文献速递造血干细胞移植与细胞治疗血栓与止血

低剂量地西他滨治疗移植后难治性 prolonged 孤立性血小板减少症:随机多中心试验

Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial.
PubMed 文献 · Blood Adv · 2021-01-01

该随机多中心试验纳入91例可评估患者,比较低剂量地西他滨联合重组人血小板生成素、单用地西他滨与常规治疗对异基因造血干细胞移植后难治性 prolonged 孤立性血小板减少症(RPIT)的疗效。三组第28天血小板恢复应答率分别为66.7%、73.3%和19.4%(P < .001),地西他滨组1年生存率优于常规治疗组。

要点

  • 低剂量地西他滨可改善移植后RPIT患者的血小板恢复。
  • 地西他滨组1年生存率优于常规治疗组。
  • 应答者巨核细胞、内皮细胞及细胞因子指标改善。

核心结论

  • 低剂量地西他滨改善移植后RPIT患者的血小板恢复及总生存。

研究设计与样本

  • 随机多中心临床试验,91例可评估患者随机分配至A组(低剂量地西他滨15 mg/m2每日静脉注射第1-3天联合重组人血小板生成素300 U/kg每日)、B组(单用地西他滨)或C组(常规治疗)。

主要发现

  • 第28天血小板恢复应答率A组66.7%、B组73.3%、C组19.4%(P < .001)。
  • 1年生存率A组64.4% ± 9.1%、B组73.4% ± 8.8%,两组相似(P = .662),均优于C组41.0% ± 9.8%(P = .025)。
  • 对地西他滨应答的患者中,巨核细胞、内皮细胞及与巨核细胞迁移和内皮损伤相关的细胞因子得到改善。

临床怎么用

  • 对于异基因造血干细胞移植后发生RPIT的患者,可考虑使用低剂量地西他滨以促进血小板恢复并改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Refractory prolonged isolated thrombocytopenia (RPIT) is an intractable complication after allogeneic hematopoietic cell transplantation (HCT), which often leads to poor prognosis. A clinical study was designed to validate the efficacy and safety of low-dose decitabine for RPIT after HCT and explore the related underlying mechanisms. Eligible patients were randomly allocated to receive 1 of 3 interventions: arm A, low-dose decitabine (15 mg/m2 daily IV for 3 consecutive days [days 1-3]) plus recombinant human thrombopoietin (300 U/kg daily); arm B, decitabine alone; or arm C, conventional treatment. The primary end point was the response rate of platelet recovery at day 28 after treatment. Secondary end points included megakaryocyte count 28 days after treatment and survival during additional follow-up of 24 weeks. Among the 91 evaluable patients, response rates were 66.7%, 73.3%, and 19.4% for the 3 arms, respectively (P < .001). One-year survival rates in arms A (64.4% ± 9.1%) and B (73.4% ± 8.8%) were similar (P = .662), and both were superior to that in arm C (41.0% ± 9.8%; P = .025). Megakaryocytes, endothelial cells (ECs), and cytokines relating to megakaryocyte migration and EC damage were improved in patients responding to decitabine. This study showed low-dose decitabine improved platelet recovery as well as overall survival in RPIT patients after transplantation. This trial was registered at www.clinicaltrials.gov as #NCT02487563.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tang Y, Chen J, Liu Q, et al. Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial. Blood Adv. 2021. PMID: 33646303. doi:10.1182/bloodadvances.2020002790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。